Neurology Consultation

MCP's neurology programme addresses CNS and PNS disorders through the intersection of neurology, immunology, and genetic medicine. The clinic evaluates conditions including multiple sclerosis, ALS, Alzheimer's and Parkinson's disease, chronic fatigue syndrome, neuroinfections, and movement disorders — integrating neurological examination with immune function testing and neurogenetic analysis to identify treatable contributors. This interdisciplinary approach makes MCP particularly valuable for patients whose neurological symptoms lack a clear diagnosis despite standard workups.

Neurological conditions are among the most diagnostically challenging in medicine. MCP's neurology programme was built on the recognition that many neurological disorders — from multiple sclerosis to chronic fatigue syndrome — have measurable immune and genetic components that conventional neurology outpatient services rarely assess systematically. The examination covers the full range of CNS and PNS conditions: neuroinfections, neuromuscular disorders, demyelinating diseases (multiple sclerosis), motor neuron diseases (ALS), neurodegenerative conditions (Alzheimer's, Parkinson's), movement disorders, and chronic fatigue syndrome of suspected neurological origin. The clinical assessment includes: - **Detailed neurological anamnesis** — symptom timeline, cognitive changes, motor/sensory changes, family history - **Clinical neurological examination** — reflexes, coordination, cranial nerve testing, sensory testing, cognitive screening - **Neurological blood panel** — B12, folate, thyroid function (neurological manifestations of thyroid disease), copper/ceruloplasmin (Wilson's disease), ferritin, inflammatory markers (CRP, ESR), autoimmune encephalitis antibodies - **Neuroinfection screen** — Lyme borreliosis (neuroborreliosis), HSV, EBV, CMV, enterovirus - **Neurogenetic analysis** — targeted DNA analysis for hereditary neurological conditions: familial Alzheimer's (APOE4, APP, PSEN1/2), Parkinson's (LRRK2, SNCA, PARK2), Huntington's, hereditary motor neuropathies, MTHFR (folate metabolism affecting neurological risk) - **Genomic screening option** — full whole-genome screening including neurological disease risk in higher-tier packages Stem cell preservation is recommended by MUDr. Klubal's team for patients with early-stage neurodegenerative diagnoses, as peripheral blood haematopoietic stem cells collected before significant disease progression offer the best therapeutic potential for future cellular therapies. The written report integrates findings across all domains and provides a diagnostic impression, a differential, and a recommended management pathway — including specialist referrals for neuroimaging (MRI, PET) where indicated.